Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Promising new inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 4- arylcoumarin and monoterpenoid moieties as components of complex antitumor therapy. / Khomenko, Tatyana M.; Zakharenko, Alexandra L.; Chepanova, Arina A. и др.
в: International Journal of Molecular Sciences, Том 21, № 1, 126, 01.01.2020.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Promising new inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 4- arylcoumarin and monoterpenoid moieties as components of complex antitumor therapy
AU - Khomenko, Tatyana M.
AU - Zakharenko, Alexandra L.
AU - Chepanova, Arina A.
AU - Ilina, Ekaterina S.
AU - Zakharova, Olga D.
AU - Kaledin, Vasily I.
AU - Nikolin, Valeriy P.
AU - Popova, Nelly A.
AU - Korchagina, Dina V.
AU - Reynisson, Jóhannes
AU - Chand, Raina
AU - Ayine-tora, Daniel M.
AU - Patel, Jinal
AU - Leung, Ivanhoe K.H.
AU - Volcho, Konstantin P.
AU - Salakhutdinov, Nariman F.
AU - Lavrik, Olga I.
N1 - Publisher Copyright: © 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme in humans, and a current and promising inhibition target for the development of new chemosensitizing agents due to its ability to remove DNA damage caused by topoisomerase 1 (Top1) poisons such as topotecan and irinotecan. Herein, we report our work on the synthesis and characterization of new Tdp1 inhibitors that combine the arylcoumarin (neoflavonoid) and monoterpenoid moieties. Our results showed that they are potent Tdp1 inhibitors with IC50 values in the submicromolar range. In vivo experiments with mice revealed that compound 3ba (IC50 0.62 μM) induced a significant increase in the antitumor effect of topotecan on the Krebs-2 ascites tumor model. Our results further strengthen the argument that Tdp1 is a druggable target with the potential to be developed into a clinically-potent adjunct therapy in conjunction with Top1 poisons.
AB - Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme in humans, and a current and promising inhibition target for the development of new chemosensitizing agents due to its ability to remove DNA damage caused by topoisomerase 1 (Top1) poisons such as topotecan and irinotecan. Herein, we report our work on the synthesis and characterization of new Tdp1 inhibitors that combine the arylcoumarin (neoflavonoid) and monoterpenoid moieties. Our results showed that they are potent Tdp1 inhibitors with IC50 values in the submicromolar range. In vivo experiments with mice revealed that compound 3ba (IC50 0.62 μM) induced a significant increase in the antitumor effect of topotecan on the Krebs-2 ascites tumor model. Our results further strengthen the argument that Tdp1 is a druggable target with the potential to be developed into a clinically-potent adjunct therapy in conjunction with Top1 poisons.
KW - Cancer
KW - Chemical space
KW - Coumarin
KW - DNA repair enzymes
KW - Molecular modeling
KW - Neoflavone
KW - Tdp1 inhibitor
KW - Topoisomerase 1 inhibitors
KW - Topotecan
KW - Tumor
KW - EMPIRICAL SCORING FUNCTIONS
KW - TOPOISOMERASE-I
KW - BIOLOGICAL EVALUATION
KW - chemical space
KW - topotecan
KW - CONSTITUENTS
KW - coumarin
KW - IDENTIFICATION
KW - ENHANCE
KW - neoflavone
KW - molecular modeling
KW - tumor
KW - PROTEIN-LIGAND DOCKING
KW - topoisomerase 1 inhibitors
KW - RHABDOMYOSARCOMA
KW - IRINOTECAN
KW - cancer
KW - COUMARIN DERIVATIVES
UR - http://www.scopus.com/inward/record.url?scp=85077279055&partnerID=8YFLogxK
U2 - 10.3390/ijms21010126
DO - 10.3390/ijms21010126
M3 - Article
C2 - 31878088
AN - SCOPUS:85077279055
VL - 21
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 1
M1 - 126
ER -
ID: 22997516